Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report)’s share price traded up 3.9% during mid-day trading on Thursday. The company traded as high as $3.46 and last traded at $3.46. 362,350 shares traded hands during trading, an increase of 39% from the average session volume of 261,100 shares. The stock had previously closed at $3.33.
Aadi Bioscience Trading Down 1.8%
The stock has a market cap of $80.02 million, a P/E ratio of -1.42 and a beta of 0.68. The firm’s 50-day simple moving average is $3.89 and its 200 day simple moving average is $3.81.
About Aadi Bioscience
Aadi Bioscience, Inc is a biopharmaceutical company focused on developing and commercializing therapies for patients with genetically defined cancers. The company’s primary product is FYARRO (sirolimus protein-bound particles for injectable suspension), an albumin-bound formulation of sirolimus designed to deliver an mTOR inhibitor to tumors.
FYARRO received approval from the U.S. Food and Drug Administration in 2021 for the treatment of adults with advanced unresectable or metastatic malignant perivascular epithelioid cell tumors, or PEComa, who require systemic therapy.
Featured Articles
- Five stocks we like better than Aadi Bioscience
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
